Floatz logo

gb5005 cart

Refractory Lymphoma

The First Affiliated Hospital of Xiamen UniversityCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

288 Active assets in the Refractory Lymphoma cohort.

View all 50

Same molecule, other indications

gb5005 cart is also rated in:

Chimeric Antigen Receptor T-cellDormant
CC
Indicative ·
43 / 100
View asset →
non-Hodgkin lymphomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →